Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026

Worldwide third-quarter 2026 net trade sales of DARZALEX, including the subcutaneous product, were $4.239 billion, according to Johnson & Johnson. Sales were $2.528 billion in the U.S. and $1.711 billion in the rest of the world; Genmab receives royalties on worldwide sales.

Analysis

DARZALEX is a meaningful royalty-linked asset for Genmab, so the key market question is not the reported sales level but whether growth is translating into incremental royalty revenue and changing Genmab’s forward earnings trajectory. This release gives no comparable period, royalty rate, or cash/recognition timing; it cannot establish acceleration. For J&J, the product’s scale is strategically useful, but the consolidated equity sensitivity is likely much lower than GMAB’s—verify against segment disclosures rather than treating product sales as J&J earnings growth.

Over 1–3 months, the catalyst is Genmab’s next reported royalty revenue and outlook: sales could rise while royalty economics, mix, or timing disappoint. Over 6–18 months, competitive substitution in multiple myeloma and lifecycle developments could affect durability; track share, treatment-duration, and regimen data, including competition from Sanofi’s Sarclisa. The contrarian point is that a large quarterly sales figure can look bullish without proving momentum, while investors may also underappreciate how much GMAB’s earnings sensitivity depends on continued durability of a partnered product. No valuation or sales trend is supplied, so a directional trade is not justified on this release alone.

Key Decisions for Investors

• No immediate trade from this announcement alone; do not infer growth from a single-quarter sales figure.
• For GMAB, monitor the next earnings disclosure for DARZALEX royalty revenue, year-over-year sales trajectory, and any change to guidance. Reassess positively only if reported royalties and outlook confirm durable growth.
• Treat JNJ as a lower-sensitivity exposure to this product-specific signal; avoid extrapolating DARZALEX sales directly into consolidated earnings.
• Falsifiers for a constructive GMAB view: deceleration in reported sales, royalty revenue lagging sales, weaker forward guidance, or evidence of competitive share loss in myeloma regimens.